Microbial transport company COPAN Diagnostics Inc on Thursday reported the shipment of 5 millionth UTM (Universal Transport Medium) from its new additional 38,000-square-foot manufacturing facility in Carlsbad, CA on 20 October 2020 in the battle against COVID-19.
Within a few months, the additional space has drastically increased the UTM production in the US from a former capacity of several thousand test kits per week to more than 840,000 a week. The transport medium is packaged in a plastic, screw cap tube and maintains organism viability for 48 hours at room or refrigerated temperature, according to the company.
The company's US FDA-cleared transport systems are shipped to hospitals, reference labs and other urgent point-of-care sites to collect specimens from patients being tested for the SARS-CoV-2 virus.
With a goal to hit 1m a week, the company has decided to add additional manufacturing capabilities to serve the healthcare needs.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial